Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey.
Prophylactic treatment of rhesus macaques with 10(4)-10(6) U/kg of recombinant human interferon-gamma (rHuIFN-gamma) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-gamma and rHuIFN-alpha A.
Morrill
J C
JC
Disease Assessment Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011.
Czarniecki
C W
CW
Peters
C J
CJ
D000818:Animals; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006403:Hematologic Tests; D006801:Humans; D007370:Interferon Type I / Q000097:blood / Q000627:therapeutic use; D007371:Interferon-gamma / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008253:Macaca mulatta; D011994:Recombinant Proteins; D012295:Rift Valley Fever / Q000517:prevention & control*
D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma